Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib With Induction and Consolidation Chemotherapy in Newly Diagnosed AML (Japan, Phase 1b)
jRCT2080223254Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of quizartinib in acute myeloid leukemia (AML) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of quizartinib in combination with standard chemotherapy and Pharmacokinetics of quizartinib and AC886. Started Jun 2016; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223254.